Lung Cancer and Antibody Drug Conjugates

We don't have the data yet to indicate that these agents are superior to our standard approaches in lung cancer specifically based on, for instance, randomized data. But having these agents in my hand in clinical trials, I'm very hopeful on the outcomes of some of these trials. We're seeing sort of a duration of response in particular with these agents that we have not typically seen with chemotherapy approaches in the salvage setting.